Dr. Donald Kohn has been developing gene therapies for rare pediatric immune disorders for over 30 years. This week, his role ...
Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 March 27, 2026 8:30 ...
Respondents to a survey note an urgent need for role-specific training to bridge knowledge gaps in advanced-therapy ...
After multiple delays, the US regulator has approved Kresladi as the first gene therapy for severe leukocyte adhesion deficiency-I.
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces it has been recognised with the ‘Most Innovative CDMO (Cell & Gene Therapy)’ award at the CDMO ...
The Food and Drug Administration approved on Thursday a gene therapy for severe leukocyte adhesion deficiency type 1 (LAD-1), ...
Academics innovate gene therapy manufacturing to cut costs and improve access, addressing commercialization challenges and ...
Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agreement, Belief BioMed will grant Grand Life ...
Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...
Etranacogene dezaparvovec (Hemgenix), the only commercially available gene therapy for hemophilia B, is temporarily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results